Medical device manufacturers have petitioned the Union Health Ministry to revise the Drugs, Medical Devices and Cosmetics Bill, 2026. Industry leaders argue that treating engineering products like pharmaceuticals could impose harsh criminal penalties for minor documentation errors, potentially stalling growth in a sector currently valued at over USD 15 billion.
The Indian medical device industry has formally urged the Union Health Minister to reconsider the draft Drugs, Medical Devices and Cosmetics Bill, 2026, currently under inter-ministerial consultation. In a petition submitted on August 8, 2026, industry associations expressed significant concerns that the proposed legislation fails to distinguish between pharmaceutical drugs and medical devices.
At the heart of the dispute is the classification of medical devices. Manufacturers argue that devices like stents, implants, and imaging machines are engineering products, not chemical substances. They contend that the bill adopts a pharma-centric approach by using terminology such as "adulterated" and "spurious," which are typically applied to drugs. Industry stakeholders worry that this misclassification will lead to regulatory confusion and impose compliance requirements that are ill-suited for the technical nature of medical hardware.
The most significant concern for companies and investors is the inclusion of criminal penalties for minor regulatory lapses, such as labeling errors or documentation oversights. Manufacturers warn that these provisions could expose leadership and firms to imprisonment even when no patient harm occurs. Industry bodies argue that this approach deviates from global regulatory frameworks, such as those used by the US FDA or the European Union Medical Device Regulation (EU MDR). These international standards typically focus on quality management systems and risk-based conformity assessments rather than criminalization for administrative errors.
This legislative debate arrives as India actively seeks to position itself as a global hub for medical device manufacturing. The sector, valued at over USD 15 billion, was a central focus at the 'India Medical Device 2026' conference held on August 7–8. A stringent regulatory environment could potentially deter domestic and foreign investment, as companies may become wary of the legal and operational risks involved in navigating a framework designed for the pharmaceutical industry.
The government's recent regulatory tone further adds to the uncertainty. On August 6, 2026, the Health Ministry notified new rules empowering regulators to debar pharmaceutical firms found submitting fake or fabricated data. While this move is aimed at improving drug quality, the medical device industry fears that a similarly rigid, one-size-fits-all enforcement approach will fail to account for the unique manufacturing challenges inherent in the MedTech space.
For investors and stakeholders, the key monitorable will be how the government addresses these petitions during the ongoing consultation process. Any revisions that align the bill with international quality standards while removing or softening criminal penalties for non-material errors would be a positive signal for the sector’s operational stability and future growth.